Carboplatin plus paclitaxel improves quality of life in ovarian cancer
the ONA take:
There is no significant quality of life advantage of cisplatin plus topotecan compared with paclitaxel plus carboplatin in the treatment of women with newly diagnosed ovarian cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
A recent phase 3 study in women with newly diagnosed stage 2B or greater ovarian cancer found that cisplatin plus topotecan followed by carboplatin plus paclitaxel had a significantly lower response rate vs paclitaxel plus carboplatin. The study also demonstrated no significant difference in progression-free survival at 43 months of follow-up.
In this analysis, researchers sought to evaluate the impact of each regimen on quality of life. Results showed that global quality of life, physical symptoms, fatigue, and various function scores significantly improved in both groups, but there was no significant difference between the arms. Researchers found that nausea and vomiting improve more with paclitaxel plus carboplatin during and after treatment.
The findings of this analysis combined with the efficacy results of the phase 3 trial suggest that carboplatin plus paclitaxel should continue to be the standard of care for patients with newly diagnosed ovarian cancer.
There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|